What is Cordella?
Cordella represents a paradigm shift in the management of advanced heart failure, moving beyond traditional episodic care toward a continuous, data-driven model. The Cordella Heart Failure System integrates a cloud-based disease management platform with a breakthrough implantable wireless pulmonary artery pressure sensor. This technology enables clinicians to perform at-home hemodynamic management, facilitating the early detection of worsening heart failure symptoms before they necessitate hospitalization.
By providing a comprehensive, reimbursable solution, the company addresses a critical gap in the healthcare market. Its position as a leader in remote patient monitoring and diagnostic innovation allows it to deliver improved patient outcomes while simultaneously reducing the economic burden on healthcare systems. The platform's ability to synthesize complex physiological data into actionable clinical insights positions it as a cornerstone of modern cardiovascular care.
How much funding has Cordella raised?
Cordella has raised a total of $128.7M across 10 funding rounds:
Debt
$1.2M
Private Equity
$1.6M
Debt
$2.2M
Debt
$3M
Series B
$3M
Series C
$32M
Debt
$12M
Series D
$70M
Debt
$2M
Debt (2013): $1.2M, investors not publicly disclosed
Private Equity (2014): $1.6M, investors not publicly disclosed
Debt (2014): $2.2M, investors not publicly disclosed
Debt (2015): $3M, investors not publicly disclosed
Series B (2015): $3M, investors not publicly disclosed
Series C (2016): $32M led by APERTURE Venture Partners, Lumira Capital, BioVentures Investors, and SV Life Sciences
Debt (2017): $12M supported by Silicon Valley Bank
Series D (2019): $70M featuring Seroba Life Sciences, APERTURE Venture Partners, Wanxiang Healthcare Investments, Life Sciences Partners, Lumira Capital, OSF Ventures, Bioventures Investors, SV Health Investors, and Skydeck LLC
Debt (2020): $2M backed by PPP
Key Investors in Cordella
Seroba Life Sciences
A European venture capital firm specializing in high-impact innovations within the biotech and medtech sectors, focused on supporting entrepreneurs to realize commercial and clinical ambitions.
APERTURE Venture Partners
A healthcare-focused investment firm dedicated to fostering growth in medical devices, diagnostics, and healthcare IT, with a proven track record of backing companies that achieve significant market valuations.
Wanxiang Healthcare Investments
A corporate-backed venture group targeting early to growth-stage healthcare technologies, with a specific emphasis on digital health and long-term strategic partnership.
What's next for Cordella?
With the support of its latest strategic investment, Cordella is poised to accelerate its commercial footprint and deepen its clinical evidence base. The focus remains on scaling the adoption of the Cordella Heart Failure System across diverse healthcare networks, ensuring that the technology becomes a standard of care for patients suffering from chronic heart conditions. Future strategic initiatives will likely prioritize the integration of advanced analytics and machine learning to further refine predictive capabilities, alongside potential expansion into broader diagnostic applications within the life sciences ecosystem. As the company transitions into its next phase of maturity, the emphasis will shift toward long-term value creation and the sustained improvement of global healthcare delivery standards.
See full Cordella company page
